Drug Profile
TQB 2858
Alternative Names: TQB-2858Latest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; Transforming growth factor beta replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Sarcoma
- Phase I Cervical cancer; Nasopharyngeal cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 22 Jan 2024 Chia Tai Tianqing Pharmaceutical Group terminates a phase I trial in Sarcoma (Inoperable/unresectable, Recurrent, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) due to sponsor's decision (NCT05262101)
- 18 Jan 2024 Chia Tai Tianqing Pharmaceutical Group terminates a phase-I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (IV), due to the current clinical research status of dual antibody drugs and full communication with the investigators (NCT05154630)
- 08 Dec 2023 Chia Tai Tianqing Pharmaceutical Group terminates a Phase-I trial in Pancreatic cancer (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease) in China (IV) due to the adjustment of sponsor's development strategies and pipeline (NCT05193604)